LIANG CONGXIN has a total of 22 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 1999. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are PULMAGEN THERAPEUTICS ASTHMA LTD, CHEN GUOQING PAUL and BERGMAN JEFFREY M.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 13 | |
#2 | WIPO (World Intellectual Property Organization) | 7 | |
#3 | China | 1 | |
#4 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Liang Congxin | 22 |
#2 | Li Zhigang | 4 |
#3 | Tang Peng Cho | 3 |
#4 | Blake Robert A | 2 |
#5 | Guan Huiping | 2 |
#6 | Miller Todd Anthony | 1 |
#7 | Tran Ngoc My | 1 |
#8 | Holmberg Par | 1 |
#9 | He Yuanjun | 1 |
#10 | Nematalla Asaad | 1 |
Publication | Filing date | Title |
---|---|---|
CN108366994A | Novel Jak1 selective depressants and application thereof | |
WO2018005713A1 | Piperazine derivatives as trpml modulators | |
WO2005097137A2 | Advanced quinazoline based protein kinase inhibitors |